Literature DB >> 21187093

Involvement of miR-21 in resistance to daunorubicin by regulating PTEN expression in the leukaemia K562 cell line.

Haitao Bai1, Rang Xu, Zhongwei Cao, Daolin Wei, Chun Wang.   

Abstract

Recent studies have shown microRNA-21 (miR-21) is overexpressed in several types of cancer and contributes to tumor resistance to chemotherapy. In this study, we investigated whether miR-21 mediated resistance of the leukaemia cell line K562 to the chemotherapeutic agent daunorubicin (DNR). miR-21 expression was upregulated in the DNR resistant cell line K562/DNR compared to its parental line K562. Stable transfection of miR-21 induced drug resistance in K562, while suppression of miR-21 in K562/DNR led to enhanced DNR cytotoxicity. Additional experiments indicate that the mechanism of miR-21 drug resistance involves the PI3K/Akt pathway and changes following PTEN protein expression. This study provides a novel mechanism for understanding leukaemia drug resistance.
Copyright © 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21187093     DOI: 10.1016/j.febslet.2010.12.027

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  43 in total

1.  miR-181a sensitizes resistant leukaemia HL-60/Ara-C cells to Ara-C by inducing apoptosis.

Authors:  Haitao Bai; Zhongwei Cao; Chong Deng; Lili Zhou; Chun Wang
Journal:  J Cancer Res Clin Oncol       Date:  2012-01-01       Impact factor: 4.553

2.  MYCN-mediated miR-21 overexpression enhances chemo-resistance via targeting CADM1 in tongue cancer.

Authors:  Guopei Zheng; Nan Li; Xiaoting Jia; Cong Peng; Liyun Luo; Yingen Deng; Jiang Yin; Ying Song; Hao Liu; Minying Lu; Zhijie Zhang; Yixue Gu; Zhimin He
Journal:  J Mol Med (Berl)       Date:  2016-04-08       Impact factor: 4.599

3.  miR-21 induces cell cycle at S phase and modulates cell proliferation by down-regulating hMSH2 in lung cancer.

Authors:  Zhiwei Zhong; Zhuo Dong; Lihua Yang; Zhaohui Gong
Journal:  J Cancer Res Clin Oncol       Date:  2012-07-18       Impact factor: 4.553

Review 4.  Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer.

Authors:  Hui Jun Lim; Philip Crowe; Jia-Lin Yang
Journal:  J Cancer Res Clin Oncol       Date:  2014-08-22       Impact factor: 4.553

Review 5.  Non-coding RNAs as theranostics in human cancers.

Authors:  Roxana S Redis; Ioana Berindan-Neagoe; Victor I Pop; George A Calin
Journal:  J Cell Biochem       Date:  2012-05       Impact factor: 4.429

Review 6.  Role of microRNAs, circRNAs and long noncoding RNAs in acute myeloid leukemia.

Authors:  Yan Liu; Zhiheng Cheng; Yifan Pang; Longzhen Cui; Tingting Qian; Liang Quan; Hongyou Zhao; Jinlong Shi; Xiaoyan Ke; Lin Fu
Journal:  J Hematol Oncol       Date:  2019-05-24       Impact factor: 17.388

7.  MiR-21 modulates chemosensitivity of tongue squamous cell carcinoma cells to cisplatin by targeting PDCD4.

Authors:  Wenhao Ren; Xiaolong Wang; Ling Gao; Shaoming Li; Xiaojing Yan; Jin Zhang; Chen Huang; Yincheng Zhang; Keqian Zhi
Journal:  Mol Cell Biochem       Date:  2014-03-11       Impact factor: 3.396

8.  MicroRNA-21 regulates the sensitivity of diffuse large B-cell lymphoma cells to the CHOP chemotherapy regimen.

Authors:  Haitao Bai; Ju Wei; Chong Deng; Xiaoyu Yang; Chun Wang; Rang Xu
Journal:  Int J Hematol       Date:  2012-12-30       Impact factor: 2.490

9.  Interaction of the oncogenic miR-21 microRNA and the p53 tumor suppressor pathway.

Authors:  Xiaodong Ma; Saibyasachi N Choudhury; Xiang Hua; Zhongping Dai; Yong Li
Journal:  Carcinogenesis       Date:  2013-02-05       Impact factor: 4.944

Review 10.  Sweating the small stuff: microRNAs and genetic changes define pancreatic cancer.

Authors:  Siuwah Tang; Jillian Bonaroti; Sebnem Unlu; Xiaoyan Liang; Daolin Tang; Herbert J Zeh; Michael T Lotze
Journal:  Pancreas       Date:  2013-07       Impact factor: 3.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.